

ADR Focus by Elizabeth Rudy, DVM, RPh

Drugs That Induce Heart Failure: An Overview (Part 1 and 2)

References

1. Tham YL, Verani Ms, Chang J. Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer. *Breast Cancer Res Treat* 2002;74:131-134.
2. Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. *Drug Saf* 2006;29(7):567-586.
3. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. *Breast* 2004;13:173-183.
4. Tan C, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. *Cancer* 1967;20:333-353.
5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment, and prevention. *Drug Saf* 2000;22:263-302.
6. Rosen GM, Halpern HJ. Spin trapping biologically generated free radicals: correlating formation with cellular injury. *Methods Enzymol* 1990;18:611-621
7. Von Hoff DD, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 1979;91:710-717.
8. Legha SS, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. *Ann Intern Med* 1982;96:133-139.
9. Eisenhauser EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. *Drugs* 1998;55:5-30.
10. Dowd NP, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. *J Clin Invest* 2001:585-590.
11. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention: review of the literature. *Med Sci Monit* 2000;6:411-420.
12. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? *Cancer* 2004;100:2052-2063.
13. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. *J Cancer Res Clin Oncol* 2004;130:1-7.
14. Deyton LR, et al. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi's sarcoma. *N Engl J Med* 1989;321:1246-1249.
15. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. *Chest* 1991;99:557-561.
16. Kragel AH, et al. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. *Cancer* 1990;66:1513-1516.
17. White RL, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. *Cancer* 1994;74:3212-3222.
18. Chung ES, et al. Randomized double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in

(continued on next page)

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2007 by the University of Washington
Also published at <http://uw.pnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

- patients with moderate-to-severe heart failure. *Circulation* 2003;107:3133-3140.
19. Kwon HJ, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Ann Intern Med* 2003;138:807-811.
 20. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. *Ann Rev Med* 2001;52:239-257.
 21. Delea TE, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. *Diabetes Care* 2003;26:2983-2989.
 22. Bresalier RS, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Eng J Med* 2005;352:1092-1102.
 23. Solomon SD, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Eng J Med* 2005; 2005;352:1071-1080.
 24. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. *Drug Safety* 2000; 22(4):263-302.
 25. Acosta D, Ramos K. Cardiotoxicity of tricyclic antidepressants in primary cultures of rat myocardial cells. *J Toxicol Environ Health* 1984;14(2-3):137-143.
 26. Killian JG, et al. Myocarditis and cardiomyopathy associated with clozapine. *Lancet* 1999;354:1841-1845.
 27. Hägg S, et al. Myocarditis related to clozapine treatment. *J Clin Psychopharmacol* 2001;21:382-388.
 28. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med* 2004;141:764-770.
 29. Souverein PC, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. *Heart* 2004;90:859-865.
 30. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole [Letter]. *Lancet* 2001;357:1766-1767.
 31. Arsura EL, et al. Amphotericin B-induced dilated cardiomyopathy. *Am J Med* 1994;97(6):560-562.
 32. Danaher PJ, et al. Reversible dilated cardiomyopathy related to amphotericin B therapy. *J Antimicrob Chemother* 2004;53:115-117.
 33. Moyssakis I, et al. Reversible dilated cardiomyopathy associated with amphotericin B treatment. *Int J Antimicrob Agents* 2005;25:444-447.
 34. Abenhaim L, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. *N Engl J Med* 1996;335:609-616.
 35. Jollis JG, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. *Circulation* 2000;101:2071-2077.
 36. Gardin JM, et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. *JAMA* 2001;286:2011-2014.
 37. Zannad F, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. *Am Heart J* 2002;144:508-515.
 38. Wilke A, et al. Mitral, aortic, and tricuspid valvular heart disease associated with ergotamine therapy for migraine [Letter]. *Eur Heart J* 1997;16:701.
 39. Hauck AJ, et al. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. *Arch Pathol Lab Med* 1990;114(1):62-64.
 40. Schade R, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. *N Engl J Med* 2007;356:29-38.
 41. Zanettini R, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. *N Engl J Med* 2007;356:39-46.